Humacyte (HUMA) announced the commercial launch of Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible. The U.S. Food and Drug Administration, FDA, granted a full approval for Symvess on December 19, 2024. The FDA has now completed its required review of commercial batch information and has authorized Humacyte to commence commercial shipments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte, Pluristyx announce expanded partnership
- Humacyte announces planned IND filing in 2025 for sdATEV for CABG
- HUMA Lawsuit Alert! Class Action Against Humacyte, Inc.
- Humacyte provides update on commerical launch, pricing of Symvess
- Hertz Global Holdings call volume above normal and directionally bullish